<?xml version="1.0" ?>
<document id="7dc484e62b5a5e470b072184f55b023d5e751061">
  <chunk id="7dc484e62b5a5e470b072184f55b023d5e751061.c0" text="Ceacam1 Separates Graft-versus-Host-Disease from Graft-versus-Tumor Activity after Experimental Allogeneic Bone Marrow Transplantation"/>
  <chunk id="7dc484e62b5a5e470b072184f55b023d5e751061.c1" text="Background: Allogeneic bone marrow transplantation (allo-BMT) is a potentially curative therapy for a variety of hematologic diseases, but benefits, including graft-versus-tumor (GVT) activity are limited by graft-versus-host-disease (GVHD). Carcinoembryonic antigen related cell adhesion molecule 1 (Ceacam1) is a transmembrane glycoprotein found on epithelium, T cells, and many tumors. It regulates a variety of physiologic and pathological processes such as tumor biology, leukocyte activation, and energy homeostasis. Previous studies suggest that Ceacam1 negatively regulates inflammation in inflammatory bowel disease models.">
    <entity charOffset="259-266" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e0" ontology_id="CHEBI_59132" text="antigen" type="chemical"/>
    <entity charOffset="289-297" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e1" ontology_id="CHEBI_25367" text="molecule" type="chemical"/>
    <entity charOffset="329-341" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e2" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="598-624" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e3" ontology_id="DOID_0050589" text="inflammatory bowel disease" type="disease"/>
    <entity charOffset="617-624" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e4" ontology_id="DOID_4" text="disease" type="disease"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e0" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e3" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.p0" relation="true"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e0" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e4" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.p1" relation="true"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e1" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e3" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.p2" relation="true"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e1" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e4" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.p3" relation="true"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e2" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e3" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.p4" relation="true"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e2" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c1.e4" id="7dc484e62b5a5e470b072184f55b023d5e751061.c1.p5" relation="true"/>
  </chunk>
  <chunk id="7dc484e62b5a5e470b072184f55b023d5e751061.c2" text="Methods: We studied Ceacam1 as a regulator of GVHD and GVT after allogeneic bone marrow transplantation (allo-BMT) in mouse models. In vivo, Ceacam1 2/2 T cells caused increased GVHD mortality and GVHD of the colon, and greater numbers of donor T cells were positive for activation markers (CD25 hi , CD62L lo ). Additionally, Ceacam1 2/2 CD8 T cells had greater expression of the gut-trafficking integrin a 4 b 7 , though both CD4 and CD8 T cells were found increased numbers in the gut posttransplant. Ceacam1 2/2 recipients also experienced increased GVHD mortality and GVHD of the colon, and alloreactive T cells displayed increased activation. Additionally, Ceacam1 2/2 mice had increased mortality and decreased numbers of regenerating small intestinal crypts upon radiation exposure. Conversely, Ceacam1-overexpressing T cells caused attenuated target-organ and systemic GVHD, which correlated with decreased donor T cell numbers in target tissues, and mortality. Finally, graft-versus-tumor survival in a Ceacam1 + lymphoma model was improved in animals receiving Ceacam1 2/2 vs. control T cells.">
    <entity charOffset="239-244" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e0" ontology_id="CHEBI_17499" text="donor" type="chemical"/>
    <entity charOffset="239-244" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e1" ontology_id="CHEBI_17891" text="donor" type="chemical"/>
    <entity charOffset="916-921" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e2" ontology_id="CHEBI_17499" text="donor" type="chemical"/>
    <entity charOffset="916-921" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e3" ontology_id="CHEBI_17891" text="donor" type="chemical"/>
    <entity charOffset="1023-1031" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e4" ontology_id="DOID_0060058" text="lymphoma" type="disease"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e0" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e4" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.p0" relation="true"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e1" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e4" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.p1" relation="true"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e2" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e4" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.p2" relation="true"/>
    <pair e1="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e3" e2="7dc484e62b5a5e470b072184f55b023d5e751061.c2.e4" id="7dc484e62b5a5e470b072184f55b023d5e751061.c2.p3" relation="true"/>
  </chunk>
</document>
